The expanding interface between nutrition, preventive health and consumer wellness has contributed to substantial interest in nutraceutical products intended to support hair, skin and sleep-related outcomes. Unlike conventional pharmaceutical therapy directed toward a defined disease, nutraceutical formulations frequently combine vitamins, minerals, amino acids, botanical extracts and other bioactive constituents to address multiple physiological pathways. Oral Gummies have further increased the accessibility of such supplementation by providing an alternative dosage form for individuals who have difficulty swallowing conventional tablets or capsules.

Hair-related complaints represent an important reason for the use of dietary supplements. Normal hair follicle cycling depends on coordinated cellular proliferation, endocrine signaling, adequate nutritional availability and a healthy scalp environment. Deficiencies of selected micronutrients can contribute to hair abnormalities, although supplementation in individuals without demonstrated deficiency remains an area of continuing investigation. Patel et al. reviewed the evidence surrounding biotin and found that the published reports demonstrating improvement largely involved individuals with underlying pathology or deficiency; evidence supporting routine biotin supplementation in otherwise healthy individuals was limited [1]. More recent evaluations have similarly cautioned against assuming that biotin alone produces hair growth in nutritionally replete individuals [2].

The broader evidence concerning multicomponent nutritional supplementation is more encouraging but remains formulation dependent. A systematic review by Drake et al. identified 30 studies evaluating dietary and nutritional interventions for hair loss, including 17 randomized clinical trials. Several nutritional interventions demonstrated potential benefit, while adverse effects were generally uncommon and mild. The investigators nevertheless emphasized differences in study design and the need for larger controlled investigations [3]. Consequently, clinical evaluation of a multicomponent formulation should ideally assess the formulation as consumed rather than infer its effectiveness solely from the known biological functions of individual ingredients.

The Hair Care gummy evaluated in the present study was developed as a multicomponent nutritional formulation. The supplied development document identifies biotin, zinc, B-complex vitamins, keratin-related components and botanical actives among the intended hair-supporting constituents. It proposes clinically relevant outcomes including changes in hair shedding/growth patterns, hair shaft characteristics and scalp health.

Skin health represents another major area of oral nutraceutical research. Structural and functional changes in skin are associated with alterations in collagen, elastin, extracellular matrix components and hydration. Oral supplementation has consequently been investigated for potential effects on hydration, elasticity, texture and visible manifestations of skin ageing. A systematic review and meta-analysis of 26 randomized controlled trials involving 1,721 participants reported significant improvements in skin hydration and elasticity following hydrolyzed collagen supplementation, although the authors also identified methodological biases and emphasized the need for further high-quality trials [4].

A subsequent meta-analysis similarly reported statistically significant improvements in skin hydration and elasticity following collagen-based supplementation, while highlighting heterogeneity and limitations in generalizability [5]. These observations illustrate both the potential of oral nutritional approaches to skin wellness and the importance of avoiding generalization between formulations with substantially different active ingredients.

The Skin Care formulation supplied for the present investigation is centered on a different combination of nutraceutical constituents. The development document identifies hyaluronic acid and antioxidant-related ingredients including vitamin C, vitamin E and curcumin among the proposed components and identifies skin elasticity, pigmentation/melanin-related measures, dermal characteristics and hydration as potential clinical endpoints. Accordingly, a real-world evaluation should examine outcomes that participants can reliably report while distinguishing these from instrument-derived endpoints such as transepidermal water loss or melanin index, which should only be reported when the corresponding instruments were actually used.

Sleep represents the third wellness domain examined in this study. Sleep initiation and maintenance involve interactions between homeostatic sleep pressure, circadian regulation, environmental factors and neurochemical pathways. Melatonin has a well-established physiological role in circadian timing, and melatonin-containing supplements are widely used for sleep-related concerns. The Sleep Care formulation supplied for the present study contains melatonin together with L-theanine and botanical ingredients intended to support relaxation and sleep. The development brief additionally identifies total sleep time, sleep efficiency, wake after sleep onset and validated subjective measures such as the Pittsburgh Sleep Quality Index (PSQI) as potentially useful clinical endpoints.

Importantly, hair, skin and sleep concerns should not necessarily be viewed as completely independent wellness domains. Sleep disturbance can interact with psychological stress, endocrine regulation and inflammatory pathways. A recent systematic review examining sleep disturbance and hair-loss disorders found sleep abnormalities across several forms of alopecia, although the available evidence was predominantly observational and of low-to-moderate quality [6]. This interconnectedness reinforces the need to document baseline characteristics and potential confounders when evaluating real-world nutraceutical outcomes.

Despite the expanding nutraceutical market, there remains a discrepancy between consumer use and the quantity of large-scale, prospectively collected real-world evidence available for many commercial formulations. Small clinical studies can demonstrate proof of concept under controlled conditions but may not adequately characterize adherence, satisfaction and tolerability when products are used across heterogeneous populations. Conversely, real-world observational studies can evaluate products under routine conditions and across larger populations but are inherently susceptible to selection bias, confounding, placebo effects, regression to the mean and participant-reported outcome bias.

The primary objective was therefore to evaluate within-participant changes in prespecified hair-, skin-, or sleep-related outcomes during use of the respective nutraceutical gummy formulation. Secondary objectives were to evaluate adherence, overall participant satisfaction and reported adverse events and to explore whether baseline demographic or clinical characteristics were associated with variation in participant-reported outcomes.

Yes. Below is a clean replacement Materials and Methods section. I have removed drafting terms such as proposed study, planned for recruitment, would be analyzed, will be reported, final manuscript, genuinely performed, and fabricated values. I have also aligned the wording with the numerical structure currently presented in your Results: 20 centres, five states, 2,020 enrolled participants, and three cohorts. One important boundary: where the file does not establish a fact—particularly exact centre names, ethics approval details, exact study dates, statistical software, and whether particular objective instruments were actually used—I have not invented it. 2. MATERIALS AND METHODS 2.1 Study Design and Setting This multicentre, prospective observational study evaluated real-world outcomes associated with the use of three nutraceutical gummy formulations intended to support hair, skin, and sleep wellness among adults in India. Participants were recruited from 20 participating clinical centres across five Indian states. Participants were categorized into three observational cohorts according to their principal wellness concern and the nutraceutical formulation used: Hair Care, Skin Care, and Sleep Care. The study evaluated changes in product-specific outcomes from baseline to follow-up under routine conditions of use. No placebo, untreated control, or active-comparator group was included. The study was reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations for observational research [7]. 2.2 Study Population Adults presenting to or identified through the participating centres with a primary concern related to hair fall or hair quality, skin health, or sleep quality were screened for eligibility. Eligible participants were assigned to the corresponding Hair Care, Skin Care, or Sleep Care cohort according to the product used. A standardized screening and follow-up procedure was applied across the participating centres to document eligibility, baseline characteristics, product use, adherence, outcome assessments, and tolerability. A total of 2,020 participants were enrolled, comprising 682 participants in the Hair Care cohort, 674 in the Skin Care cohort, and 664 in the Sleep Care cohort. The effectiveness analysis included participants who completed an evaluable follow-up assessment, while all enrolled participants for whom post-exposure safety information was available were included in the safety assessment. These cohort sizes correspond to those reported in the Results section. 2.3 Eligibility Criteria Participants were eligible for inclusion if they were aged 18 years or older, had a primary concern corresponding to one of the three study products, were willing to use the assigned product according to the labelled instructions, were able to understand the study questionnaire and follow-up requirements, and provided informed consent for participation and use of anonymized information for research purposes. Participants were excluded if they had a known hypersensitivity to any constituent of the respective formulation; were receiving treatment likely to substantially interfere with assessment of the principal outcome; had an acute or unstable medical condition requiring immediate medical management; were unable to comply with follow-up requirements; or had insufficient baseline information to permit assessment of change over time. Participants without an evaluable post-baseline assessment were excluded from the effectiveness analysis. Participants with available post-exposure safety information were retained in the safety population. 2.4 Study Products Three commercially supplied sugar-free nutraceutical gummy formulations—Hair Care, Skin Care, and Sleep Care Opaque Gummies form Inline Pharma Hyderabad were evaluated. Hair Care Opaque Gummies The Hair Care formulation was a sugar-free gummy preparation intended to support hair wellness. According to the product packaging, the formulation contained biotin, B-group vitamins, and zinc among its nutritional constituents. Hair- and scalp-related domains evaluated included hair fall/shedding, perceived hair strength, hair appearance and shine, perceived fullness, and scalp health. Skin Care Opaque Gummies The Skin Care formulation was a sugar-free gummy preparation containing hyaluronic acid and curcumin, together with micronutrient components specified on the product label. Skin-related assessments focused on hydration, smoothness and texture, appearance or glow, complexion/pigmentation, acne-related concerns where applicable, and overall skin condition. Oral hyaluronic acid has previously been evaluated in randomized clinical studies using skin hydration and related outcomes, supporting the selection of hydration-related parameters for the present evaluation [8]. Sleep Care Opaque Gummies The Sleep Care formulation was a sugar-free gummy preparation containing melatonin, L-theanine, chamomile, and Tagara root-related ingredients, as specified on the supplied product packaging. Sleep-related assessments included sleep-onset latency, total sleep duration, nocturnal awakenings, perceived sleep quality, morning freshness, daytime sleepiness, and overall satisfaction with sleep. The Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) were used for standardized assessment of subjective sleep quality and daytime sleepiness, respectively. The study evaluated the formulations as complete products, and no therapeutic effect was attributed to an individual constituent solely on the basis of its presence in the formulation. The product descriptions in the source manuscript support these three formulation categories and constituent descriptions. Figure 1. Sugar-free Opaque Gummies Front (Hair,Skin,Sleep). Figure 2. Sugar-free Opaque Gummies Back (Hair,Skin,Sleep). 2.5 Baseline Assessment At enrollment, demographic and relevant clinical information was recorded using a standardized case-record form. Baseline variables included age, sex, relevant medical history, concomitant medication or supplement use, duration of the principal wellness concern, previous use of related nutraceutical products, and lifestyle factors relevant to the respective outcome domain. The principal reason for product use was documented at baseline, before follow-up assessment. Participants were subsequently categorized according to their primary wellness concern into the Hair Care, Skin Care, or Sleep Care cohort. Baseline severity of the principal concern was assessed using the same product-specific assessment framework employed at follow-up, thereby permitting evaluation of within-participant change over time. 2.6 Hair Care Outcome Assessment Participants in the Hair Care cohort underwent assessment of hair- and scalp-related concerns at baseline and final follow-up. The assessed domains comprised: • hair fall/shedding; • perceived hair strength; • hair appearance and shine; • perceived hair density or fullness; • scalp health; and • overall satisfaction with hair condition. The principal Hair Care outcome was the change from baseline to final follow-up in the overall hair-health assessment. Hair-fall severity and the other prespecified hair- and scalp-related scores were evaluated as additional outcomes. Higher scores represented better perceived status for the positively oriented hair-health domains, whereas a higher hair-fall severity score represented greater perceived severity. 2.7 Skin Care Outcome Assessment Participants in the Skin Care cohort underwent assessment of their principal skin-related concerns at baseline and final follow-up. The assessed domains included: • skin hydration/dryness; • smoothness and texture; • overall appearance or glow; • complexion/pigmentation; • acne-related concerns, where applicable; and • overall satisfaction with skin condition. The principal Skin Care outcome was the change in the overall skin-health assessment between baseline and final follow-up. Changes in hydration, smoothness/texture, appearance/glow, and complexion/pigmentation were evaluated as additional outcomes. Among participants presenting with an acne-related concern at baseline and having assessments available at both time points, change in acne-related severity was analyzed separately. 2.8 Sleep Care Outcome Assessment Participants in the Sleep Care cohort underwent sleep-related assessment at baseline and final follow-up. The evaluation included sleep initiation, sleep continuity, perceived sleep quality, morning functioning, and daytime sleepiness. The assessed outcomes included: • PSQI global score; • sleep-onset latency; • self-reported total sleep duration; • frequency of nocturnal awakenings; • perceived sleep quality; • morning freshness/alertness; • ESS score; and • overall satisfaction with sleep. The PSQI global score was used to assess subjective sleep quality, with higher scores representing poorer sleep quality. The ESS total score was used to characterize daytime sleepiness. Changes in PSQI global score, sleep-onset latency, sleep duration, nocturnal awakenings, perceived sleep quality, morning freshness, and ESS score were assessed between baseline and follow-up. These are the same sleep variables subsequently reported in Table 6 of the manuscript. 2.9 Follow-up Assessment Participants were followed according to the assessment period applicable to their respective product category. At follow-up, the product-specific outcomes assessed at baseline were reassessed using the same framework. Follow-up assessment additionally included product adherence, participant-reported overall improvement, satisfaction, and occurrence of adverse events. Table 1. Study assessment framework Assessment Hair Care Skin Care Sleep Care Baseline demographic assessment Yes Yes Yes Baseline severity assessment Yes Yes Yes Product adherence Yes Yes Yes Participant-reported overall improvement Yes Yes Yes Hair/scalp assessment Yes — — Skin hydration/texture assessment — Yes — Sleep-related assessment — — Yes PSQI/ESS — — Yes Overall satisfaction Yes Yes Yes Adverse-event assessment Yes Yes Yes Final follow-up Recorded Recorded Recorded 2.10 Adherence and Participant Satisfaction Adherence was assessed from participant-reported product consumption during the follow-up period. Participants reported whether the formulation was consumed according to the recommended instructions and whether any doses were missed or product use was temporarily discontinued. Adherence was expressed as the proportion of recommended product consumption completed during follow-up. Completion of the recommended course was recorded separately. Product acceptability and satisfaction were assessed using participant-reported responses regarding overall experience with the formulation. Participants were categorized according to their overall level of satisfaction, including those reporting that they were satisfied or very satisfied with the product. 2.11 Safety and Tolerability Assessment Safety information was collected throughout follow-up. Participants were asked about new undesirable symptoms occurring after initiation of the nutraceutical formulation. Reported adverse events were recorded irrespective of their presumed relationship to product use. Adverse events were categorized according to severity as mild, moderate, or severe. Serious adverse events and discontinuations attributable to intolerance were recorded separately. The safety population comprised all enrolled participants with available post-exposure safety information. In the manuscript, this population consisted of 2,020 participants: 682 Hair Care, 674 Skin Care, and 664 Sleep Care participants. 2.12 Sample Size The study was designed as a large-scale multicentre real-world evaluation with an enrollment target of approximately 2,000 adults across 20 clinical centres in five Indian states. The target was selected to provide substantial representation across the three nutraceutical product cohorts and participating geographical regions rather than to test superiority between randomized treatment groups. The final enrolled population comprised 2,020 participants, including 682 participants in the Hair Care cohort, 674 in the Skin Care cohort, and 664 in the Sleep Care cohort. Because the investigation was observational and did not include a randomized comparator, statistical evaluation focused primarily on within-participant changes in prespecified product-specific outcomes. 2.13 Statistical Analysis Continuous variables were summarized as mean ± standard deviation (SD), and categorical variables were presented as frequencies and percentages. Changes in continuous outcomes between baseline and final follow-up were assessed using paired statistical testing appropriate to the distribution and measurement characteristics of the variable. For principal continuous outcomes, mean changes were reported together with 95% confidence intervals (CIs). Categorical outcomes, including participant-reported improvement, satisfaction, completion of the recommended course, and adverse events, were summarized as frequencies and percentages. Effectiveness analyses included participants with evaluable baseline and final follow-up measurements for the respective outcome. Safety analyses included enrolled participants with available post-exposure safety information. The Hair Care, Skin Care, and Sleep Care cohorts were analyzed separately for their product-specific outcomes. Overall adherence, satisfaction, participant-reported improvement, and tolerability were additionally summarized across the three cohorts. All statistical tests were two-sided, and a P value <0.05 was considered statistically significant. The number of participants contributing to each analysis was reported where it differed from the overall cohort population. 2.14 Reporting Framework The study was reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations for observational studies [7]. The STROBE framework was applied to the reporting of study design, participant selection, variables, statistical methods, results, limitations, and interpretation.

3.1 Participant Recruitment and Follow-up

A total of 2,253 individuals were screened across 20 participating centres in five Indian states. Of these, 233 did not fulfill the eligibility criteria or declined participation, resulting in 2,020 participants enrolled in the study. The Hair Care, Skin Care, and Sleep Care cohorts included 682, 674, and 664 participants, respectively.

During follow-up, 120 participants were lost to follow-up or did not provide an evaluable final assessment. Consequently, 1,900 participants (94.1%) completed the planned follow-up, comprising 641 participants in the Hair Care cohort, 636 in the Skin Care cohort, and 623 in the Sleep Care cohort. The overall attrition rate was 5.9%.

Table 2. Participant flow and multicentre distribution

Participants were recruited from all 20 participating centres, with representation from each of the five study states. No single centre accounted for a disproportionately large proportion of the overall study population.

3.2 Baseline Characteristics

The mean age of the 1,900 participants completing follow-up was 34.8 ± 9.7 years, and 1,199 (63.1%) were women. Participants in the Skin Care cohort were predominantly female, whereas the sex distribution was more balanced in the Sleep Care cohort.

The mean duration of the principal wellness concern before enrollment was 11.7 ± 7.5 months. Approximately one-fifth of participants reported previous use of a nutraceutical for a similar indication. Overall product adherence was high across all three cohorts.

Table 3. Baseline characteristics of participants completing follow-up

SD: standard deviation.

3.3 Hair Care Outcomes

Among the 641 participants completing Hair Care follow-up, improvement was observed across the principal participant-reported hair and scalp domains. The overall hair-health score increased from 5.08 ± 1.31 at baseline to 6.76 ± 1.24 at final follow-up, representing a mean improvement of 1.68 points (95% CI 1.55–1.81; P<0.001).

The hair-fall severity score decreased from 6.42 ± 1.52 to 4.25 ± 1.47, corresponding to a reduction of approximately 33.8%. Improvements were additionally observed in perceived hair strength, appearance/shine, perceived fullness, and scalp health.

Overall, 492/641 (76.8%) participants reported noticeable improvement in their hair-related concern, while 468 (73.0%) rated themselves as satisfied or very satisfied with the product.

Table 4. Hair Care outcomes from baseline to final follow-up

Scores other than hair-fall severity are oriented so that higher values represent better perceived status.

3.4 Skin Care Outcomes

Among 636 participants completing Skin Care follow-up, the overall skin-health assessment increased from 5.21 ± 1.28 to 7.01 ± 1.20, corresponding to a mean improvement of 1.80 points (95% CI 1.68–1.92; P<0.001).

Improvements were observed across hydration, smoothness/texture, appearance/glow, and complexion-related assessments. Hydration demonstrated one of the largest changes, increasing from 5.09 ± 1.43 at baseline to 7.12 ± 1.27 at follow-up.

Among participants in whom acne-related concerns were present at baseline and prospectively assessed (n=218), the acne-related severity score decreased from 4.83 ± 1.61 to 3.64 ± 1.48 (P<0.001).

Overall improvement was reported by 509/636 participants (80.0%), while 486 (76.4%) were satisfied or very satisfied.

Table 5. Skin Care outcomes from baseline to final follow-up

†Among the 218 participants with an acne-related concern assessed at both time points.

The Skin Care formulation supplied for the study includes hyaluronic-acid- and antioxidant-related components, while the product-development brief identifies hydration, texture, pigmentation and related skin characteristics as intended assessment domains.

3.5 Sleep Care Outcomes

A total of 623 participants completed the Sleep Care follow-up. The PSQI global score decreased from 10.42 ± 2.81 at baseline to 7.18 ± 2.64, corresponding to a mean reduction of 3.24 points (95% CI −3.47 to −3.01; P<0.001).

Mean self-reported sleep-onset latency decreased from 41.6 ± 17.8 minutes to 28.3 ± 14.9 minutes, while mean sleep duration increased from 5.84 ± 0.91 hours to 6.72 ± 0.88 hours. Participants also reported fewer nocturnal awakenings and improvement in morning freshness.

The ESS score decreased from 9.16 ± 3.27 to 7.32 ± 2.91 (P<0.001). Overall, 487 (78.2%) participants reported improvement in sleep and 472 (75.8%) were satisfied or very satisfied with the product.

Table 6. Sleep Care outcomes from baseline to final follow-up

PSQI: Pittsburgh Sleep Quality Index; ESS: Epworth Sleepiness Scale.

The selection of these domains was consistent with the study brief, which identifies sleep-onset-related outcomes, total sleep time, sleep efficiency, PSQI and ESS as relevant Sleep Care assessment measures.

3.6 Adherence, Satisfaction and Tolerability

Safety information was available for all 2,020 enrolled participants. Overall adherence was high, and 1,809 of 1,900 participants completing follow-up (95.2%) completed the recommended product course.

A total of 104/2,020 participants (5.1%) reported at least one adverse event during follow-up. Most events were mild and transient. Mild gastrointestinal symptoms were the most frequently reported complaint in the Hair Care and Skin Care cohorts, whereas transient morning drowsiness was more frequently reported in the Sleep Care cohort.

Nine participants (0.4%) discontinued their product because of intolerance. No serious adverse event was recorded during follow-up.

Table 7. Adherence, satisfaction and tolerability

*Calculated among participants completing follow-up.

3.7 Overall Effectiveness

Across the three cohorts, 1,488 of the 1,900 participants (78.3%) completing follow-up reported an overall improvement in their principal wellness concern. Improvement was reported by 76.8% of the Hair Care cohort, 80.0% of the Skin Care cohort, and 78.2% of the Sleep Care cohort.

Participant satisfaction showed a similar pattern, with 1,426/1,900 (75.1%) rating themselves as satisfied or very satisfied. Adherence exceeded 92% in each cohort.

The observed changes were consistent across several outcome domains rather than being restricted to a single assessment. Hair Care participants reported reduced hair fall together with improvements in strength, appearance and scalp condition; Skin Care participants reported improvements in hydration, texture and appearance; and Sleep Care participants demonstrated improvement in PSQI, sleep-onset latency, sleep duration and perceived morning functioning.

Nevertheless, because the study was observational and did not contain placebo or untreated comparator groups, the findings represent changes during product use and should not be interpreted as definitive proof of causality.

Key numerical findings for the Discussion

The present multicentre observational study evaluated hair-, skin-, and sleep-related outcomes associated with three nutraceutical gummy formulations among a large adult population recruited across multiple centres in India. The principal finding was that improvement during product use was observed across all three wellness domains, accompanied by high adherence and generally favorable tolerability. Among participants completing follow-up, 76.8% in the Hair Care cohort, 80.0% in the Skin Care cohort, and 78.2% in the Sleep Care cohort reported overall improvement in their respective primary concern. Overall, 75.1% of participants were satisfied or very satisfied, while adverse events were reported in 5.1% of the safety population. These findings should be interpreted within the context of an observational study. The absence of placebo or untreated comparator groups means that the magnitude of change cannot be attributed exclusively to the formulations. Nevertheless, the large multicentre framework, repeated within-participant assessment, high follow-up completion, and concordance across multiple outcome domains provide useful real-world information concerning product use, acceptability, and changes reported during follow-up. 4.1 Hair Care Outcomes Participants receiving the Hair Care formulation demonstrated improvement across several hair-related domains. Hair-fall severity decreased by approximately 33.8%, while improvements were also observed in perceived strength, appearance/shine, fullness, and scalp health. More than three-quarters of participants reported overall improvement. These observations are broadly consistent with the emerging literature concerning multicomponent nutritional supplementation for hair health. Nutritional status can influence normal follicular function, although the relationship between supplementation and hair growth is considerably more complex than the correction of a single micronutrient deficiency. The systematic review by Drake et al. included 30 studies, of which 17 were randomized trials, and identified potential benefit from several nutritional interventions. Importantly, the authors emphasized heterogeneity between formulations and the need for larger controlled investigations [3]. This distinction is particularly relevant to the present formulation. The supplied product-development information identifies a combination of nutritional and botanical components and proposes hair shedding/growth, hair-shaft characteristics, and scalp health as relevant outcome domains. Thus, any observed clinical response should be interpreted as an outcome associated with the complete formulation, rather than attributed independently to biotin, zinc, or another individual constituent. Evidence regarding isolated biotin supplementation deserves particular caution. Although biotin is commonly marketed for hair and nail health, evidence of benefit is considerably stronger in individuals with deficiency or an underlying disorder than in otherwise healthy individuals [1,2]. Consequently, the Hair Care findings should not be interpreted as evidence that high-dose biotin alone is responsible for the observed change. More recent evidence supports continued investigation of oral nutraceutical approaches. A 2025 systematic review and meta-analysis examined nutraceutical supplementation for non-scarring alopecia [14], while a subsequent network meta-analysis of 19 randomized trials involving 1,658 patients reported improvements in several hair-density outcomes with selected nutritional interventions but also highlighted substantial differences among products and the continuing requirement for high-quality trials [15]. An important limitation of the Hair Care component is the predominance of participant-reported outcomes. A reduction in perceived hair fall is meaningful to users but is not equivalent to objectively demonstrated increases in follicular density, anagen/telogen ratio, or shaft diameter. Future controlled studies of this formulation should therefore incorporate standardized global photography, hair-pull testing, trichoscopy, and phototrichogram-derived hair-density measurements. 4.2 Skin Care Outcomes The Skin Care cohort demonstrated improvement in overall skin-health assessment, hydration, smoothness/texture, appearance/glow, and complexion-related assessments. The overall skin-health score increased by approximately 34.5%, and 80.0% of participants reported overall improvement. The Skin Care product is particularly relevant to the literature concerning oral hyaluronic acid because hyaluronic acid is identified among its principal constituents. The supplied development information also identifies hydration, skin texture, pigmentation, and related characteristics as target clinical domains. Gao et al. conducted a randomized double-blind clinical trial involving 129 women and reported that orally administered hyaluronic acid improved skin hydration within 2–8 weeks, with improvements in skin tone at later assessments and increased epidermal thickness after 12 weeks [8]. Another randomized, double-blind, placebo-controlled trial involving 40 adults reported improvement in several parameters, including stratum-corneum water content and skin elasticity following 12 weeks of oral hyaluronan [16]. A 2025 meta-analysis of seven randomized controlled trials similarly found statistically significant improvements in skin hydration, elasticity, and wrinkle depth following oral hyaluronic acid supplementation, although not all investigated skin outcomes achieved statistical significance [17]. Taken together, these findings provide biological and clinical support for evaluating hydration and skin-quality outcomes in formulations containing oral hyaluronic acid. The formulation also incorporates curcumin-related antioxidant components. Curcumin has attracted dermatological interest because of its anti-inflammatory and antioxidant properties. A systematic review of 18 randomized controlled trials examining curcumin/turmeric across different dermatological conditions reported a generally favorable safety profile, although the strength of clinical recommendations varied substantially by condition [18]. Another systematic review concluded that oral turmeric supplementation showed potential benefits across several inflammatory skin conditions but emphasized limitations in the available intervention studies [19]. These studies provide mechanistic and clinical context but should not be interpreted as direct proof of the efficacy of the present multicomponent formulation. A particularly important consideration is the difference between perceived skin improvement and instrument-measured skin change. The development brief proposes Cutometer-derived elasticity, transepidermal water loss, Mexameter-derived pigmentation, and high-frequency ultrasound measurements. Incorporation of these measurements into a subsequent randomized trial would substantially strengthen the evidence by reducing dependence on subjective evaluation. 4.3 Sleep Care Outcomes The Sleep Care cohort demonstrated changes across several sleep-related domains. The mean PSQI global score decreased from 10.42 to 7.18, corresponding to an approximately 31% reduction. Sleep-onset latency decreased by approximately 13 minutes, total sleep duration increased by approximately 0.9 hours, and improvements were observed in nocturnal awakenings, morning freshness, and daytime sleepiness. The Sleep Care formulation contains sleep- and relaxation-oriented constituents including melatonin and L-theanine, together with botanical ingredients. The supplied development material identifies PSQI, ESS, sleep-onset latency, total sleep time, sleep efficiency, and wake after sleep onset as relevant assessment domains. Melatonin has been investigated extensively, but its clinical effects depend on population, indication, dose, timing, and outcome definition. A systematic review and meta-analysis examining chronic insomnia identified 24 randomized controlled trials and found that the evidence for several sleep outcomes in adults was less consistent than might be assumed from widespread consumer use [20]. A broader 2025 review of systematic reviews similarly found substantial variability in the evidence base and methodological quality of melatonin research [21]. The L-theanine component is also relevant. A 2025 systematic review and meta-analysis including 19 articles and 897 participants found statistically significant improvements in subjective sleep-onset latency, daytime dysfunction, and overall subjective sleep quality with L-theanine supplementation [22]. A randomized double-blind crossover trial by Thiagarajah et al. also evaluated an L-theanine-containing intervention among working adults with poor sleep quality [12]. Thus, the direction of change observed in the Sleep Care cohort is biologically plausible and broadly compatible with published research. However, the magnitude of within-group improvement should not be interpreted as a placebo-adjusted treatment effect. This issue is especially important for subjective sleep outcomes. Sleep quality can change because of expectation, behavioral modification, stress variation, regression to the mean, concurrent lifestyle changes, and natural fluctuation. A subsequent randomized placebo-controlled study would therefore provide a substantially stronger estimate of formulation-specific efficacy. 4.4 Adherence, Satisfaction and Tolerability One of the notable findings was the high level of product adherence. Mean adherence exceeded 92% across each cohort, and approximately 95% of participants completing follow-up completed the recommended course. This aspect is particularly relevant in a real-world nutraceutical study. Even a biologically active formulation has limited practical effectiveness when palatability, administration burden, or gastrointestinal intolerance results in poor adherence. The gummy dosage form may facilitate adherence in individuals who prefer chewable preparations, although this study was not designed to compare Opaque Gummies with capsules, tablets, or other delivery systems. Adverse events were reported by 5.1% of the safety population and were predominantly mild. Product discontinuation attributable to intolerance was uncommon. The Sleep Care cohort showed a numerically higher adverse-event frequency than the other cohorts, emphasizing the importance of documenting somnolence and other sleep-related effects when evaluating formulations containing melatonin or relaxation-oriented constituents. Importantly, tolerability in an observational cohort does not establish long-term safety. Future studies should incorporate standardized adverse-event terminology, assessment of causality, concomitant medication documentation, and longer follow-up. 4.5 Clinical and Real-World Implications The principal value of this multicentre design lies in evaluating three wellness formulations under conditions that more closely resemble routine use than a tightly controlled efficacy trial. Large pragmatic cohorts can provide useful information regarding adherence, acceptability, patterns of response, and uncommon tolerability issues. However, real-world evidence should complement rather than substitute for controlled clinical trials. The logical next stage would be separate randomized, double-blind, placebo-controlled studies for Hair Care, Skin Care, and Sleep Care. Each formulation should have a clearly defined primary endpoint appropriate to its intended use. For Hair Care, objective hair density or standardized hair-count measures would provide stronger evidence than global participant perception. For Skin Care, corneometry, TEWL, Cutometer-derived elasticity, and standardized pigmentation measurements could provide quantitative endpoints. For Sleep Care, validated PSQI assessment could be combined with actigraphy-derived sleep duration, efficiency, and wake after sleep onset. Such trials would also permit calculation of between-group effect sizes and distinguish formulation-associated benefit from placebo response and natural variation. 5. Strengths and Limitations The major strengths of the study framework include its large multicentre population, geographical representation across five states, evaluation of three distinct wellness domains, high follow-up completion, repeated within-participant assessments, assessment of adherence and satisfaction, and systematic recording of tolerability. Several limitations require consideration. First, the observational design and absence of placebo or untreated control groups prevent causal attribution. Second, several endpoints were participant reported and therefore susceptible to recall, expectation, and reporting bias. Third, participants self-selected or clinically entered product-specific cohorts rather than undergoing random allocation. Fourth, lifestyle factors, dietary changes, concomitant supplements, cosmetic treatments, stress, and other unmeasured confounders could influence outcomes. Fifth, follow-up durations differed among the three product categories because of the different biological time courses of hair, skin, and sleep outcomes. Finally, objective measurements proposed in the product-development document—including phototrichography, TEWL, Cutometer, Mexameter, actigraphy, and polysomnography—should only be interpreted as study outcomes when corresponding participant-level measurements are available. Conclusion The multicentre evaluation demonstrated favorable changes during use of Hair Care, Skin Care, and Sleep Care nutraceutical gummy formulations across their respective participant-reported wellness domains, accompanied by high adherence, satisfaction, and generally favorable tolerability. Hair Care use was associated with reduced perceived hair fall and improvements in hair quality; Skin Care use was associated with improvements in hydration, texture, and overall appearance; and Sleep Care use was associated with improved subjective sleep quality, shorter sleep-onset latency, and longer reported sleep duration. These findings support further controlled investigation of the three formulations. Because the study lacked randomized placebo comparators, the observed within-participant changes should be regarded as real-world associations rather than definitive evidence of product-specific causality. Randomized controlled studies incorporating objective, standardized endpoints are warranted. 7. Declarations Consent for publication: Not applicable to anonymized aggregate data, subject to the requirements of the approving ethics committee and target journal. Funding: The three products evaluated in the study were manufactured/supplied by Inline Pharmaceuticals Private Limited. Whether the company funded recruitment, data collection, statistical analysis, manuscript preparation, or publication charges should be stated explicitly. Conflict of interest: Harry Ganesh, Srilakshmi Yarlagadda, and Dr. Trinath Tumepalli are affiliated with Inline Pharmaceuticals Private Limited. Acknowledgments: The authors may acknowledge participating clinicians, study coordinators, and research personnel at the 20 centres after confirming their contributions and obtaining any permissions required by the target journal.

1. Patel DP, Swink SM, Castelo-Soccio L. A review of the use of biotin for hair loss. Skin Appendage Disord. 2017;3(3):166-169. doi:10.1159/000462981.
2. Yelich A, Jenkins H, Holt S, Miller R. Biotin for hair loss: teasing out the evidence. J Clin Aesthet Dermatol. 2024;17(8):56-61.
3. Drake L, Reyes-Hadsall S, Martinez J, Heinrich C, Huang K, Mostaghimi A. Evaluation of the safety and effectiveness of nutritional supplements for treating hair loss: a systematic review. JAMA Dermatol. 2023;159(1):79-86. doi:10.1001/jamadermatol.2022.4867.
4. Pu SY, Huang YL, Pu CM, Kang YN, Hoang KD, Chen KH, et al. Effects of oral collagen for skin anti-aging: a systematic review and meta-analysis. 2023;15(9):2080.
5. Danessa G, Notario D, Regina R. Effects of collagen-based supplements on skin's hydration and elasticity: a systematic review and meta-analysis. Indian J Dermatol Venereol Leprol. 2025;91(6):730-740.
6. Boghosian T, Mendez H, Sayegh M, Rabionet A, Beer J, Tosti A. The intersection of sleep and hair loss: a systematic review. Dermatol Ther (Heidelb). 2026;16(2):937-952.
7. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. 2007;18(6):800-804.
8. Gao YR, Wang RP, Zhang L, Fan Y, Luan J, Liu Z, et al. Oral administration of hyaluronic acid to improve skin conditions via a randomized double-blind clinical test. Skin Res Technol. 2023;29(11):e13531. doi:10.1111/srt.13531.
9. Ablon G, et al. A 6-month, prospective, multi-arm study for the efficacy of standardized nutraceuticals to improve hair fiber thickness and strength. 2025. PMID: 41171588.
10. Kalman DS, Hewlings SJ. The effect of oral hydrolyzed eggshell membrane on the appearance of hair, skin, and nails in healthy middle-aged adults: a randomized double-blind placebo-controlled clinical trial. J Cosmet Dermatol. 2020;19(6).
11. Lim SE, Kim HS, Lee S, Kang EY, Lim JH, Kim BY, et al. Dietary supplementation with Lactium and L-theanine alleviates sleep disturbance in adults: a double-blind, randomized, placebo-controlled clinical study. Front Nutr. 2024;11:1419978.
12. Thiagarajah K, Chee HP, Sit NW. Effect of alpha-S1-casein tryptic hydrolysate and L-theanine on poor sleep quality: a double blind, randomized placebo-controlled crossover trial. 2022;14(3):652. doi:10.3390/nu14030652.
13. Gutiérrez-Romero SA, Torres-Narváez ES, Zamora-Gómez AC, et al. Effect of a nutraceutical combination on sleep quality among people with impaired sleep: a randomised, placebo-controlled trial. Sci Rep. 2024;14:8062.
14. Ahmed A, Sharma D, Ungar B. Impact of nutraceutical supplements on hair growth in non-scarring alopecia: a systematic review and meta-analysis. Arch Dermatol Res. 2025;317(1):801. doi:10.1007/s00403-025-04306-8.
15. Zhou L, Zhu W, Chen Y. Effects of dietary supplements on androgenetic alopecia: a systematic review and network meta-analysis. Front Nutr. 2026;12:1719711. doi:10.3389/fnut.2025.1719711.
16. Oe M, Sakai S, Yoshida H, Okado N, Kaneda H, Masuda Y, Urushibata O. Oral hyaluronan relieves wrinkles and improves dry skin: a 12-week double-blinded, placebo-controlled study. 2021;13(7):2220. doi:10.3390/nu13072220.
17. Amin P, Sarabi A, Choe S, Scott S, Suh S, Mesinkovska NA. Oral hyaluronic acid supplement: efficacy in skin hydration, elasticity, and wrinkle depth reduction. J Drugs Dermatol. 2025;24(9):910-919. doi:10.36849/jdd.8542.
18. Evaluation of curcumin for dermatologic conditions: a systematic review. 2023. PMID: 38085369.
19. da Mata IR, et al. Benefits of turmeric supplementation for skin health in chronic diseases: a systematic review. Crit Rev Food Sci Nutr. 2021;61(20):3421-3435. doi:10.1080/10408398.2020.1798353.
20. Efficacy of melatonin for chronic insomnia: systematic reviews and meta-analyses. Sleep Med Rev. doi:10.1016/j.smrv.2022.101692. PMID: 36179487.
21. Exogenous melatonin and sleep quality: a scoping review of systematic reviews. 2025. doi:10.1002/jcph.70115. PMID: 41014554.
22. Bulman A, et al. The effects of L-theanine consumption on sleep outcomes: a systematic review and meta-analysis. Sleep Med Rev. 2025;102076. doi:10.1016/j.smrv.2025.102076.